Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 40

Results For "NIV"

815 News Found

Pfizer announces Talzenna and Xtandi combination data from phase 3 study
News | February 18, 2023

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI


Need a paradigm shift for popularising ayurveda in India
News | February 07, 2023

Need a paradigm shift for popularising ayurveda in India

For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions


Umesh Kunte appointed CEO of Albert David
People | February 06, 2023

Umesh Kunte appointed CEO of Albert David

A pharma industry veteran with over three decades of experience in domestic as well as international markets


AstraZeneca India expands ‘Ganga Godavari Cancer Screening’ initiative
News | February 04, 2023

AstraZeneca India expands ‘Ganga Godavari Cancer Screening’ initiative

The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years


Budget 2023-24: Industry welcomes focus on medical research and pharma innovation
Policy | February 02, 2023

Budget 2023-24: Industry welcomes focus on medical research and pharma innovation

It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047


CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
Drug Approval | January 31, 2023

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%


ExeGi Pharma gets clearance of IND application for EXE-346 a Live biotherapeutic biologic drug
Drug Approval | January 30, 2023

ExeGi Pharma gets clearance of IND application for EXE-346 a Live biotherapeutic biologic drug

This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis


NIB is playing a vital role in ensuring that quality biological products reach the health system: Dr. Mandaviya
Policy | January 29, 2023

NIB is playing a vital role in ensuring that quality biological products reach the health system: Dr. Mandaviya

It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry


Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%
News | January 24, 2023

Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%

The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility


Supriya Lifescience appoints Krishna Raghunathan as CFO
People | January 24, 2023

Supriya Lifescience appoints Krishna Raghunathan as CFO

He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group